Condition: Opiate Withdrawal Syndrome · Opioid Use · Sponsor: University of Pennsylvania
A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal.
This description comes directly from the study's public registry record.
Kyle M Kampman, MD · 215-746-2764 · Kampman@pennmedicine.upenn.edu
Matthew R Taylor · 215-746-0467 · matthew.taylor@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Mountain Manor Treatment Center | Baltimore, Maryland, United States | Not Yet Recruiting |
| University of Pennsylvania, Treatment Research Center | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05995535